SCHEMBL2931143

SCHEMBL2931143

CCOC(=O)COc1cc(C(F)(F)F)ccc1C(=O)OC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 1/20 0.52
PPARG P37231 2/20 0.47
PPARD Q03181 2/20 0.47
PPARA Q07869 2/20 0.47
ESR1 P03372 1/20 0.46
TDP1 Q9NUW8 1/20 0.45
IDH1 O75874 2/20 0.45
CYP2C19 P33261 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
MRGPRX4 Q96LA9 2/20 0.43
PTGDR2 Q9Y5Y4 2/20 0.43
ALDH1A1 P00352 3/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
KDM4E B2RXH2 1/20 0.42
USP2 O75604 1/20 0.42
HPGD P15428 1/20 0.42
HSD17B10 Q99714 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31577730 0.90 CFTR (0.57) CFTRPPARGPPARDPPARATDP1
SCHEMBL12630099 0.82 CFTR (0.57) CFTRPPARGPPARDPPARATDP1
SCHEMBL5620982 0.82 ESR1 (0.49) PPARGPPARDPPARAESR1IDH1
SCHEMBL958734 0.81 CYP2C19 (0.53) CFTRTDP1CYP2C19CYP1A2CYP2C9
SCHEMBL12100459 0.81 TDP1 (0.52) TDP1CYP1A2CYP2C9ALDH1A1HPGD
SCHEMBL2226597 0.81 TDP1 (0.48) TDP1CYP2C19CYP1A2CYP2C9ALDH1A1
SCHEMBL5277497 0.80 ESR1 (0.50) PPARGPPARDPPARAESR1CYP2C19
SCHEMBL25336183 0.79 CFTR (0.54) CFTRPPARGPPARDPPARACYP2C19
SCHEMBL1451872 0.79 CFTR (0.53) CFTRPPARGPPARDPPARATDP1
SCHEMBL5320603 0.78 MRGPRX4 (0.57) PPARDPPARAESR1TDP1CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7812177-B2 Potassium channel opener having benzofuroindole skeleton ANYGEN CO., LTD. (KR) 2010-10-12 US disclosed
EP-1861092-B1 POTASSIUM CHANNEL OPENER HAVING BENZOFUROINDOLE SKELETON ANYGEN CO LTD (KR) 2010-09-15 EP disclosed
EP-1861092-A4 POTASSIUM CHANNEL OPENER HAVING BENZOFUROINDOLE SKELETON ANYGEN CO LTD (KR) 2009-04-15 EP disclosed
US-20080194837-A1 Potassium Channel Opener Having Benzofuroindole Skeleton ANYGEN CO., LTD. (KR) 2008-08-14 US disclosed
EP-1861092-A1 POTASSIUM CHANNEL OPENER HAVING BENZOFUROINDOLE SKELETON Anygen Co., Ltd. (KR) 2007-12-05 EP disclosed
WO-2006096030-A1 POTASSIUM CHANNEL OPENER HAVING BENZOFUROINDOLE SKELETON ANYGEN CO., LTD. (KR) 2006-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194837-A1 Potassium Channel Opener Having Benzofuroindole Skeleton KCNJ2, KCNN3, KCNH2 CFTR 588/4885PPARG 4344/4885PPARD 3875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.